U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After on